Official reprint from UpToDate ©2017 UpToDate infants Treatment - UpToDate... · Lumbar puncture...
Transcript of Official reprint from UpToDate ©2017 UpToDate infants Treatment - UpToDate... · Lumbar puncture...
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 1/19
Official reprint from UpToDate
www.uptodate.com ©2017 UpToDate
Management and outcome of sepsis in term and late preterm infants
Author: Morven S Edwards, MD
Section Editors: Leonard E Weisman, MD, Sheldon L Kaplan, MD
Deputy Editor: Carrie Armsby, MD, MPH
All topics are updated as new evidence becomes available and our peer review process is complete.Literature review current through: Apr 2017. | This topic last updated: Jan 21, 2016.
INTRODUCTION — Sepsis is an important cause of morbidity and mortality among newborn infants.Although the incidence of sepsis in term and late preterm infants is low, the potential for serious adverseoutcomes, including death, is of such great consequence that caregivers should have a low threshold forevaluation and treatment for possible sepsis in neonates. The approach discussed below is consistent withguidelines published by the American Academy of Pediatrics (AAP) and the Center for Disease Control(CDC) [1,2].
The treatment and outcome of sepsis in term and late preterm infants will be reviewed here. Theepidemiology, clinical features, diagnosis, and evaluation of sepsis in term and late preterm infants, neonatalsepsis in preterm infants, the management of wellappearing infants at risk for group B streptococcalinfection, and the evaluation of febrile or illappearing newborns are discussed separately:
TERMINOLOGY — The following terms will be used throughout this discussion on neonatal sepsis:
Neonatal sepsis is classified according to the infant's age at the onset of symptoms:
®
®
(See "Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants".)(See "Clinical features and diagnosis of bacterial sepsis in the preterm infant (<34 weeks gestation)".)(See "Treatment and prevention of bacterial sepsis in the preterm infant (<34 weeks gestation)".)(See "Management of the infant whose mother has received group B streptococcal chemoprophylaxis".)(See "Febrile infant (younger than 90 days of age): Management", section on 'Neonates (28 days of ageand younger)'.)
(See "Approach to the illappearing infant (younger than 90 days of age)".)
Neonatal sepsis is a clinical syndrome in an infant 28 days of life or younger, manifested by systemicsigns of infection and isolation of a bacterial pathogen from the blood stream [3]. A consensus definitionfor neonatal sepsis is lacking [4]. (See "Clinical features, evaluation, and diagnosis of sepsis in term andlate preterm infants", section on 'Diagnosis'.)
Term infants are those born at a gestational age of 37 weeks or greater.
Late preterm infants (also called nearterm infants) are those born between 34 and 36 completedweeks of gestation [5]. (See "Late preterm infants".)
Preterm infants are those born at less than 34 weeks of gestation [5].
Earlyonset sepsis is defined as the onset of symptoms before 7 days of age, although some expertslimit the definition to infections occurring within the first 72 hours of life [6].
Lateonset sepsis is defined as the onset of symptoms at ≥7 days of age [6]. Similarly to earlyonsetsepsis, there is variability in its definition, ranging from an onset at >72 hours of life to ≥7 days of age[6,7].
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 2/19
SUPPORTIVE CARE — Symptomatic infants should be treated in a care setting with full cardiopulmonary
monitoring and support, because the clinical course of these infants can deteriorate rapidly. Although there
are no data demonstrating the importance of supportive care measures in neonates with sepsis, it is generally
accepted that the following supportive measures are critical components of management:
Severely ill patients may require ventilatory, volume, and/or vasopressor support to maintain adequate
oxygenation and perfusion. (See "Mechanical ventilation in neonates" and "Etiology, clinical manifestations,
evaluation, and management of neonatal shock".)
ONGOING DIAGNOSTIC EVALUATION
Other diagnostic considerations — In infants with suspected sepsis, additional testing for other conditions
may be warranted based on clinical signs and symptoms (table 1). It is often difficult to differentiate neonatal
sepsis from other diseases; however, given the morbidity and mortality of neonatal sepsis, empiric antibiotic
therapy should be provided (after cultures are obtained) to infants with suspected sepsis pending definitive
culturebased diagnosis. Alternative diagnoses should be entertained when an infant with suspected sepsis
has negative cultures. (See "Clinical features, evaluation, and diagnosis of sepsis in term and late preterm
infants", section on 'Differential diagnosis'.)
Lumbar puncture — If not done during the initial evaluation, a lumbar puncture (LP) should be performed in
infants, whenever possible, with cultureproven or culturenegative clinical sepsis. Clinical signs suggesting
meningitis can be lacking and blood culture may be negative in infants with meningitis. (See "Bacterial
meningitis in the neonate: Clinical features and diagnosis".)
ANTIBIOTIC THERAPY
Whom to treat — The decision to start antibiotic therapy is based on assessment of risk factors, clinical
evaluation, and laboratory tests. Indications for empiric antibiotic therapy include (see "Clinical features,
evaluation, and diagnosis of sepsis in term and late preterm infants", section on 'Evaluation and initial
management'):
Initial empiric therapy — The initial choice of parenteral antimicrobials for suspected sepsis in term and late
preterm neonates is based on the infant's age, likely pathogens, the susceptibility patterns of organisms in a
particular nursery, and the presence of an apparent source of infection (eg, skin, joint, or bone involvement)
(table 3).
Maintaining adequate oxygenation and perfusion (see "Oxygen monitoring and therapy in the newborn")
Prevention of hypoglycemia and metabolic acidosis (see "Management and outcome of neonatal
hypoglycemia")
Maintenance of normal fluid and electrolyte status (see "Fluid and electrolyte therapy in newborns")
Illappearance (see "Approach to the illappearing infant (younger than 90 days of age)")
Concerning symptoms, including temperature instability, or respiratory, cardiocirculatory, or neurologic
symptoms (see "Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants",
section on 'Clinical manifestations')
Cerebrospinal fluid (CSF) pleocytosis (white blood cell [WBC] cell count of >20 to 30 cells/microL) (table
2) (see "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on 'Interpretation of
CSF')
Confirmed or suspected maternal chorioamnionitis (see "Clinical features, evaluation, and diagnosis of
sepsis in term and late preterm infants", section on 'Maternal risk factors')
Positive blood, urine, or CSF culture (see "Clinical features, evaluation, and diagnosis of sepsis in term
and late preterm infants", section on 'Blood culture')
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 3/19
Earlyonset sepsis — The recommended empiric regimen for suspected earlyonset sepsis in a term orlate preterm infant is ampicillin 150 mg/kg per dose intravenously (IV) every 12 hours and gentamicin 4 mg/kgper dose IV every 24 hours [7,8]. We generally obtain baseline renal function tests (ie, blood urea nitrogenand creatinine levels) at the initiation of treatment with gentamicin. Serum gentamicin levels should beobtained in infants receiving a full course of antibiotics, but are not required if a treatment course of only 48hours is anticipated and renal function is normal [3,7].
The combination of ampicillin and gentamicin is effective in treating most common pathogens that causeearlyonset sepsis, including group B Streptococcus (GBS), Listeria, Enterococcus, and most isolates ofEscherichia coli (E. coli) (table 4) [1,9].
In a national surveillance study (2006 to 2008), 94 percent of all isolates in neonates were susceptible to thecombination of penicillin and gentamicin [10]. In a 10year review from a single center, 90 percent of earlyonset sepsis pathogens in term and late preterm infants were susceptible to ampicillin and/or gentamicin [11].Among six infants with earlyonset S. aureus bacteremia that was not susceptible to ampicillin andgentamicin, there were no complications before or after antibiotic therapy was adjusted based upon antibioticsusceptibility.
Ampicillin and gentamicin are preferred over ampicillin and a thirdgeneration cephalosporin (eg, cefotaxime)based upon the following:
The addition of a thirdgeneration cephalosporin to the regimen of ampicillin and gentamicin is warranted forinfants with suspected meningitis and critically ill neonates with risk factors associated with ampicillinresistantinfections (ie, prolonged rupture of membranes and/or prolonged antenatal maternal ampicillin treatment).
Lateonset sepsis — The choice of empiric therapy for lateonset sepsis depends upon whether the infantis admitted from the community, and thus is at lower risk for infection caused by a multidrugresistantpathogen, or is hospitalized since birth and thus at a higher risk.
Admitted from the community — Neonates admitted from the community are at lower risk forinfection caused by a multidrugresistant pathogen than are infants who remain hospitalized since birth. Thecombination of ampicillin and gentamicin or ampicillin and cefotaxime are regimens for empiric treatment ofsepsis without an apparent focus of infection in this setting (table 3) [6].
Ampicillin and gentamicin is generally the preferred regimen; however, local antibiotic resistance patternsmust be considered. The dosing for ampicillin is 75 mg/kg per dose intravenously (IV) every six hours; thedosing of gentamicin is 4 mg/kg per dose IV every 24 hours [7,8]. We generally obtain baseline renal functiontests (ie, blood urea nitrogen and creatinine levels) at the initiation of treatment with gentamicin. Serum
The regimen of ampicillin and a thirdgeneration cephalosporin is not more effective than the combinationof ampicillin and gentamicin [12].
The emergence of cephalosporinresistant gramnegative organisms (eg, Enterobacter cloacae,Klebsiella, and Serratia species) can occur when cefotaxime is used routinely [1,13].
Ampicillin and gentamicin are synergistic in treating infections caused by GBS and Listeriamonocytogenes. Cephalosporins are not active against L. monocytogenes.
In a large cohort study, infants who received ampicillin plus cefotaxime had a 1.5fold increase inmortality compared with those treated with ampicillin plus gentamicin (4.2 versus 1.9 percent, adjustedodds ratio 1.5, 95% CI 1.41.7) [12].
Ceftriaxone is highly bound to albumin and appears to displace bilirubin [14,15]. Although displacementof free bilirubin by ceftriaxone has not been reported, avoidance of ceftriaxone in neonates at risk foracute bilirubin encephalopathy is recommended [1]. (See "Clinical manifestations of unconjugatedhyperbilirubinemia in term and late preterm infants", section on 'Neurologic manifestations'.)
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 4/19
gentamicin levels should be obtained in infants receiving a full course of antibiotics, but are not required if atreatment course of only 48 hours is anticipated and renal function is normal [3,7].
In a national surveillance study (2006 to 2008), 96 percent of isolates from lateonset bacteremia weresusceptible to the combination of amoxicillin and gentamicin [10]. The addition of a thirdgenerationcephalosporin to an ampicillin and gentamicin regimen is warranted for neonates with suspected meningitis.(See 'Special circumstances' below.)
Hospitalized since birth — Infants who continue to be hospitalized since birth are at higher risk formultidrugresistant organisms, and therefore vancomycin is substituted for ampicillin (table 3). For terminfants >7 days of life, the dosing of vancomycin is dependent on serum creatinine (Scr) [16]:
Alternative weightdirected neonatal dosing recommendations for vancomycin in are also available (refer toLexicomp pediatric drug information).
Special circumstances — Alternative regimens based upon specific clinical circumstances include thefollowing (table 3):
Cultureproven sepsis — In neonates with cultureproven sepsis, the usual course of therapy is 10 days[1,3,13,18,19]. Longer treatment courses may be warranted if a specific focus of infection is identified (eg,meningitis, osteomyelitis, or septic arthritis). Antimicrobial therapy should be altered based upon thesusceptibility profile of the pathogen isolated.
Pathogenspecific therapy — Guidelines for the treatment of the most common causative organisms ofneonatal sepsis are (table 3):
Scr <0.7 mg/dL: 15 mg/kg/dose IV every 12 hoursScr 0.7 to 0.9 mg/dL: 20 mg/kg/dose IV every 24 hoursScr 1 to 1.2 mg/dL: 15 mg/kg/dose IV every 24 hoursScr 1.3 to 1.6 mg/dL: 10 mg/kg/dose IV every 24 hoursScr >1.6 mg/dL: 15 mg/kg/dose IV every 48 hours
Suspected meningitis – In neonates with lateonset sepsis, cefotaxime should be included in the regimenif lumbar puncture suggests meningitis (eg, CSF pleocytosis). Cefotaxime should also be added to theempiric regimen for earlyonset meningitis if the CSF Gram stain reveals gramnegative bacilli.Cefotaxime provides extended spectrum for enteric gramnegative rods and has optimal activity in theCSF against pneumococci. Treatment of bacterial meningitis in neonates is discussed in detailseparately. (See "Bacterial meningitis in the neonate: Treatment and outcome", section on 'Empiricaltherapy'.)
Suspected pneumonia − Empiric regimens for treatment of infants with a pulmonary focus of infectioninclude ampicillin and gentamicin, ampicillin and cefotaxime, vancomycin and cefotaxime, or vancomycinand gentamicin. Treatment of pneumonia in neonates is discussed in detail separately. (See "Neonatalpneumonia", section on 'Treatment'.)
If there is a focus of infection involving the soft tissues, skin, joints, or bones (in which case S. aureus is alikely pathogen), vancomycin should be substituted for ampicillin [17]. In a toxicappearing infant, nafcillinshould also be added.
If intravascular catheterrelated infection is a concern, treatment should be initiated with vancomycin andgentamicin to provide empiric coverage for coagulasenegative staphylococci, S. aureus, and gramnegative bacteria.
If infection is thought to arise from the gastrointestinal tract (eg, anaerobic bacteria), clindamycin oranother suitable agent, such as metronidazole, should be added to the therapeutic regimen to improvecoverage for these pathogens.
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 5/19
Group B streptococcus — The drug of choice for GBS is penicillin. Thus, when GBS is identified, andresolution of bacteremia is documented by a repeat blood culture and, in infants with meningitis, the CSF issterile, we recommend discontinuing gentamicin and continuing therapy with penicillin G alone (table 5AB).(See "Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'.)
Escherichia coli — In patients with Escherichia coli (E. coli) sepsis sensitive to ampicillin who haveimproved clinically and in whom meningitis has been excluded, ampicillin monotherapy is administered for a10day course.
For patients with ampicillinresistant E. coli, the choice of definitive therapy is based upon the susceptibilityprofile. Cefotaxime is often employed if the isolate is susceptible.
Other gramnegative bacilli — Nonmeningeal infections caused by E. coli, Klebsiella, Proteus,Salmonella, or Shigella should be treated with a single agent, based upon the antimicrobial susceptibilityprofile.
Antimicrobial treatment for infections caused by Enterobacter, Serratia, or Pseudomonas should be selectedbased upon the susceptibility profile of the organism.
Infections caused by multidrugresistant gramnegative bacilli, including those caused by extendedspectrumbetalactamaseproducing organisms, or those with hyperproduction of betalactamases, should be treatedwith meropenem.
Listeria monocytogenes — The combination of ampicillin and gentamicin is used for initial therapy.Treatment with both agents is more effective than ampicillin alone in vitro and in animal models of Listeriainfection. Cephalosporins are not active against L. monocytogenes. Duration of therapy usually is 10 days.(See "Treatment, prognosis, and prevention of Listeria monocytogenes infection", section on 'Antibioticregimens'.)
Staphylococcus species — Directed therapy for infection caused by staphylococci is determined bythe sensitivity of the isolate to specific antibiotic agents:
Probable but unproven sepsis — In infants with a negative blood culture but a clinical status that remainsconcerning for a systemic infection (eg, ongoing temperature instability; ongoing respiratory, cardiocirculatory,or neurologic symptoms not explained by other conditions; or laboratory abnormalities suggestive of sepsis),antibiotic therapy can be extended for as long as a total of 5 to 10 days.
After 48 hours, the empiric regimen is altered based upon whether or not meningitis has been excluded:
S. aureus – Vancomycin or, in a toxicappearing infant, vancomycin plus nafcillin should be employed forS. aureus infection until the susceptibility profile is available. The regimen then should be adjustedaccording to the susceptibility profile:
Methicillinsusceptible S. aureus (MSSA) – Treatment of MSSA infection should be completed withnafcillin. Cefazolin is an alternative for treatment of most MSSA infections outside the centralnervous system (CNS) and not involving endocarditis. (See "Staphylococcus aureus bacteremia inchildren: Management and outcome".)
•
Methicillinresistant S. aureus (MRSA) – Treatment should be completed with vancomycin. (See"Methicillinresistant Staphylococcus aureus in children: Treatment of invasive infections", section on'Treatment of neonates'.)
•
Coagulasenegative staphylococci – Coagulasenegative staphylococcal infections require treatment withvancomycin.
If meningitis has been excluded, the ampicillin regimen can be changed to 75 mg/kg every 12 hours.
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 6/19
Alternative diagnoses should also be entertained when an infant with suspected sepsis has negative cultures
(table 1). Antibiotics should be discontinued when another diagnosis is established. (See "Clinical features,
evaluation, and diagnosis of sepsis in term and late preterm infants", section on 'Differential diagnosis'.)
Infection unlikely — Empiric antibiotics are initiated in many infants with maternal risk factors, abnormal
laboratory values, and/or mild to moderate symptoms that subsequently resolve. Sepsis is unlikely in these
infants if they remain well and the blood culture is sterile at 48 hours. Empiric antibiotic therapy should be
discontinued after 48 hours in these neonates [1,20].
Response to therapy — In most cases, symptomatic infants with proven sepsis improve clinically within 24
to 48 hours.
In infants with bacteremia, a repeat blood culture should be obtained after 24 to 48 hours of therapy to
document sterility. Failure to sterilize the bloodstream suggests that the antimicrobial(s) chosen are not active
against the infecting pathogen or that there is an unrecognized focus of infection. Consultation with a pediatric
infectious disease specialist may be warranted.
ADJUNCTIVE THERAPIES — The following adjunctive immunotherapeutic interventions have been studied
in neonatal sepsis, but should NOT be routinely administered as they have not been shown to conclusivelyimprove outcomes [18,19,21]:
PREVENTION — The primary intervention to prevent neonatal sepsis is the use of intrapartum antibiotic
prophylaxis (IAP) in mothers with group B streptococcal (GBS) colonization and other risk factors. Although
IAP has resulted in a decrease in the incidence of earlyonset GBS invasive neonatal infection, it has not had
a similar impact on the rate of lateonset GBS disease. (See "Neonatal group B streptococcal disease:
Prevention" and "Group B streptococcal infection in neonates and young infants", section on 'Epidemiology'.)
Comprehensive prevention of neonatal sepsis will require a multiinterventional program including effective
maternal vaccination, reduction in preterm delivery, and limited exposure of term infants to potential
pathogens. (See "Vaccines for the prevention of group B streptococcal disease".)
OUTCOME — Overall mortality in term and late preterm infants with neonatal sepsis is approximately 2 to 4
percent [12,29]. Mortality estimates vary depending on gestational age of the infant (lower gestational age is
associated with higher mortality), pathogen (E. coli is associated with higher mortality than GBS), and sepsisdefinition (lower mortality rates tend to be reported if infants with culturenegative clinical sepsis are included
compared with cases of cultureproven sepsis only).
Mortality rates for GBS sepsis in term infants after the introduction of IAP and routine use of empirical
antibiotic therapy range from 2 to 3 percent for earlyonset disease and 1 to 2 percent for lateonset disease.
The risk of mortality is higher in infants with birth weight less than 2500 g, absolute neutrophil count less than
1500 cells/microL, hypotension, apnea, and pleural effusion [30]. (See "Group B streptococcal infection in
neonates and young infants", section on 'Outcome'.)
The risk of mortality is particularly high in neonates with earlyonset sepsis caused by E. coli. Estimatedmortality rates for term neonates with E. coli sepsis are 6 to 10 percent [9,29,31].
If lumbar puncture has not been performed, ampicillin should be continued at a meningitic dose.
Management of infants with cerebrospinal fluid (CSF) pleocytosis and/or positive CSF culture is
discussed separately. (See "Bacterial meningitis in the neonate: Treatment and outcome".)
Intravenous immunoglobulin (IVIG) infusions [22,23]
Granulocyte transfusions [24]
Granulocyte and granulocytemacrophage colonystimulating factor (GCSF and GMCSF) [25,26]
Pentoxifylline [27]
Lactoferrin [28]
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 7/19
SOCIETY GUIDELINE LINKS — Links to society and governmentsponsored guidelines from selected
countries and regions around the world are provided separately. (See "Society guideline links: Sepsis in
neonates".)
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics"
and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5 to 6
grade reading level, and they answer the four or five key questions a patient might have about a given
condition. These articles are best for patients who want a general overview and who prefer short, easyto
read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more
detailed. These articles are written at the 10 to 12 grade reading level and are best for patients who want
indepth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or email
these topics to your patients. (You can also locate patient education articles on a variety of subjects by
searching on "patient info" and the keyword(s) of interest.)
SUMMARY AND RECOMMENDATIONS
th th
th th
Basics topics (see "Patient education: Sepsis in newborn babies (The Basics)")
Although the incidence of sepsis in term and late preterm infants is low, the potential for serious adverse
outcomes, including death, is of such great consequence that caregivers should have a low threshold for
evaluation and treatment for possible sepsis. (See 'Introduction' above.)
Supportive care for symptomatic infants is delivered in an intensive care setting to ensure adequate
oxygenation, perfusion, and maintenance of normal fluid and electrolyte balance, especially in severely
affected patients. (See 'Supportive care' above.)
Indications for empiric antibiotic therapy include any of the following:
Illappearance (see "Approach to the illappearing infant (younger than 90 days of age)")•
Concerning symptoms, including temperature instability, or respiratory, cardiocirculatory, or
neurologic symptoms (see "Clinical features, evaluation, and diagnosis of sepsis in term and late
preterm infants", section on 'Clinical manifestations')
•
Cerebrospinal fluid (CSF) pleocytosis (white blood cell [WBC] cell count of >20 to 30 cells/microL)
(table 2) (see "Bacterial meningitis in the neonate: Clinical features and diagnosis", section on
'Interpretation of CSF')
•
Confirmed or suspected maternal chorioamnionitis (see "Clinical features, evaluation, and diagnosis
of sepsis in term and late preterm infants", section on 'Maternal risk factors')
•
Positive blood, urine, or CSF culture (see "Clinical features, evaluation, and diagnosis of sepsis in
term and late preterm infants", section on 'Blood culture')
•
We recommend suspected neonatal sepsis be treated initially with empiric antibiotic therapy (table 3) that
provides broad coverage for the most likely pathogens (group B Streptococcus [GBS] and gramnegativeenteric organisms, including Escherichia coli [E. coli]) (table 4) (Grade 1B).
The empiric regimen for earlyonset sepsis without an apparent focus consists of ampicillin and
gentamicin. (See 'Earlyonset sepsis' above.)
•
Empiric antibiotic regimens for lateonset sepsis without an apparent focus are as follows (see
'Lateonset sepsis' above):
•
For neonates admitted from the community, we suggest ampicillin and gentamicin.
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 8/19
Use of UpToDate is subject to the Subscription and License Agreement.
Topic 5046 Version 27.0
For infants who continue to be hospitalized from birth, we suggest vancomycin and gentamicin.
Empiric antibiotic regimens for suspected neonatal sepsis (early or lateonset) with certain special
circumstances are as follows (see 'Special circumstances' above):
•
If there is concern of lateonset meningitis, we suggest adding cefotaxime to the regimen. (See
"Bacterial meningitis in the neonate: Treatment and outcome", section on 'Empirical therapy'.)
If there is concern for pneumonia, we suggest a regimen of ampicillin and cefotaxime or
vancomycin and cefotaxime.
If there is a focus of infection involving the soft tissues, skin, joints, or bones (in which case S.aureus is a likely pathogen), we suggest substituting vancomycin or, in toxicappearing infants,vancomycin plus nafcillin for ampicillin.
If intravascular catheterrelated infection is a concern, we suggest vancomycin and gentamicin.
If an intestinal source for sepsis is suspected, we suggest adding clindamycin, or other suitable
antibiotic such as metronidazole.
Antibiotic therapy is altered based upon isolation of the causative agent and its antimicrobial
susceptibility pattern. (See 'Pathogenspecific therapy' above.)
In infants with cultureproven sepsis, the usual course of therapy is 10 days. Longer treatment is
warranted if a specific focus of infection is identified (eg, meningitis, osteomyelitis, or septic arthritis).
(See 'Cultureproven sepsis' above.)
In wellappearing infants with negative cultures after 48 hours, empiric antibiotic therapy should be
discontinued as sepsis is unlikely in these infants. (See 'Infection unlikely' above.)
Most infants with cultureproven sepsis improve clinically within 24 to 48 hours after appropriate antibiotic
treatment is started. The response to antibiotic therapy is assessed by a repeat blood culture 24 to 48
hours after initiation of antibiotic therapy. Failure to sterilize the bloodstream suggests either that the
antimicrobial(s) chosen are not active against the infecting pathogen or that there is an unrecognized
focus of infection. (See 'Response to therapy' above.)
The mortality of neonatal sepsis in term infants is less than 10 percent. (See 'Outcome' above.)
The primary intervention to prevent neonatal sepsis is the use of intrapartum antibiotic prophylaxis in
mothers with documented GBS colonization, a previous birth of an infant with GBS disease, or GBS
bacteriuria during the current pregnancy. (See "Neonatal group B streptococcal disease: Prevention".)
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 9/19
GRAPHICS
Differential diagnosis of neonatal sepsis
Diagnosis Distinguishing features Diagnostic tests
Other systemic neonatal infections
Viral infections:
Herpes simplex virus Mucocutaneous vesicles, CSF
pleocytosis, elevated CSF protein,
thrombocytopenia, hepatitis
Viral culture; HSV PCR
Enteroviruses Fulminant systemic disease,
myocarditis, hepatitis, encephalitis
Viral culture; EV PCR
Parechovirus Encephalitis/meningitis, rash on
palms and soles
HPeV PCR (available through CDC)
Cytomegalovirus Thrombocytopenia, periventricular
intracranial calcifications,
microcephaly, sensorineural hearing
loss, chorioretinitis
Viral culture; CMV PCR
Influenza viruses Respiratory symptoms, rhinorrhea,
gastrointestinal symptoms
Viral culture; influenzaspecific
antigen detection or
immunofluorescence assay
Respiratory syncytial virus Respiratory symptoms, rhinorrhea,
cough, apnea, pneumonia
Viral culture; RSVspecific antigen
detection or immunofluorescence
assay
Spirochetal infections – Syphilis Skeletal abnormalities
(osteochondritis and periostitis),
pseudoparalysis, persistent rhinitis,
maculopapular rash (particularly on
palms and soles or in diaper area)
RPR or VDRL
Parasitic infections:
Congenital malaria Anemia, splenomegaly, jaundice Detection of parasitemia on blood
smear
Toxoplasmosis Intracranial calcifications (diffuse),
hydrocephalus, chorioretinitis,
mononuclear CSF pleocytosis,
elevated CSF protein
T. gondii serology
Fungal infection – Candidiasis Persistent hyperglycemia,
thrombocytopenia, multiorgan failure
Isolation of Candida in blood, urine
or CSF culture
Noninfectious causes of temperature instability in neonates
Altered environmental
temperature
Transient; no other systemic symptoms; resolves with simple
nonpharmacologic measures
Dehydration Clinical history of poor feeding or fluid losses (eg, vomiting and/or diarrhea)
Neonatal abstinence syndrome History of maternal drug use;
sweating, sneezing, nasal stuffiness,
and yawning
Positive drug screening tests
CNS insult (eg, anoxia or
hemorrhage)
History of perinatal asphyxia; focal
neurologic findings or seizures
Abnormal neuroimaging studies
Hypothyroidism Hypotonia, lethargy, hypothermia,
large fontanels
Abnormal T4 or TSH level on
newborn screen
Congenital adrenal hyperplasia Ambiguous genitalia (females),
adrenal insufficiency and salt
wasting (hyponatremia,
hyperkalemia, dehydration)
Abnormal 17ahydroxyprogesterone
level on newborn screen
Noninfectious causes of respiratory and cardiocirculatory symptoms in neonates
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 10/19
Transient tachypnea of thenewborn
Onset of symptoms within two hoursafter delivery; symptoms usuallyresolve within 24 hours
CXR findings include increased lungvolumes, mild cardiomegaly,prominent vascular markings, fluid inthe interlobar fissures, and pleuraleffusions
Respiratory distress syndrome Most common in preterm infants;rare in term infants; onset ofsymptoms within first few hoursafter delivery, progressively worsensover first 48 hours of life
CXR findings include low lung volumeand diffuse reticulogranular groundglass appearance with airbronchograms
Meconium aspiration History of meconiumstainedamniotic fluid; respiratory distressoccurs immediately after birth
Initial CXR may show streaky, lineardensities; as the disease progresses,the lungs may appear hyperinflatedwith diffuse patchy densities
Pneumothorax Asymmetric chest rise, decreasedbreath sounds on affected side;hypotension (in cases of tensionpneumothorax)
CXR will usually detect symptomaticpneumothoraces
Congenital anomalies (includingtrachealesophageal fistula,choanal atresia, anddiaphragmatic hernia)
Often occur with other congenitalanomalies including VACTERL andCHARGE associations; choanalatresia is characterized by noisylabored breathing while feeding
CDH is often diagnosed by routineantenatal ultrasound screening;postnatal CXR shows herniation ofabdominal contents into hemithorax;TEF is diagnosed with uppergastrointestinal series and/orbronchoscopy
Neonatal abstinence syndrome History of maternal drug use;sweating, sneezing, nasal stuffiness,and yawning
Positive drug screening tests
Cardiac arrhythmias (eg,supraventricular tachycardia)
Abrupt onset and termination ofrapid heart rate
Abnormal ECG
Congenital heart disease Infants with ductaldependentlesions may initially lack symptomsthen develop cyanosis and rapidclinical deterioration as the PDAcloses in the first few days of life
Abnormal hyperoxia test; abnormalechocardiography
Noninfectious causes of neurologic symptoms in neonates
Hypoglycemia Common in infants who are large forgestational age and/or infants ofdiabetic mothers
Abnormal blood glucose level
Hypercalcemia Increased neuromuscular irritabilityand seizures; associated withprematurity, maternal diabetes, andperinatal asphyxia
Abnormal serum calcium level
Hypermagnesemia Generalized hypotonia, respiratorydepression and apnea; typicallyresults from maternal treatment withmagnesium sulfate
Abnormal serum magnesium level
CNS insult (eg, anoxia orhemorrhage)
History of perinatal asphyxia; focalneurologic findings or seizures
Abnormal neuroimaging studies
Congenital CNS malformations(eg, hydrocephalus)
Abnormal head circumference Abnormal neuroimaging studies
Neonatal abstinence syndrome History of maternal drug use;sweating, sneezing, nasal stuffiness,and yawning
Positive drug screening tests
Inborn errors of metabolism Otherwise unexplained acidbasedisorders, hyperammonemia,hypoglycemia, hematologic
Positive newborn screen for inbornerrors of metabolism
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 11/19
abnormalities, liver dysfunction, and
renal disease
Pyridoxine deficiency Refractory seizures Abnormal plasma pyridoxal5
phophate level
HSV: herpes simplex virus; PCR: polymerase chain reaction; CSF: cerebral spinal fluid; HPeV: human parechovirus; EV:
enterovirus; CMV: cytomegalovirus; RSV: respiratory syncytial virus; RPR: rapid plasma reagin; VDRL: venereal disease
research laboratory; CNS: central nervous system; T4: thyroxine; TSH: thyrotropin; CXR: chest radiograph; TEF:
tracheoesophageal fistula; CDH: congenital diaphragmatic hernia; VACTERL: malformations of the vertebrae, anus,
cardiac structures, trachea, esophagus, renal system, and limbs; CHARGE: coloboma of the iris or choroid, heart defect,
atresia of the choanae, retarded growth and development, genitourinary abnormalities, and ear defects; ECG:
electrocardiogram; PDA: patent ductus arteriosus.
Adapted from: Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the fetus and newborn infant,
7th ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010.
Graphic 100409 Version 1.0
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 12/19
Characteristics of cerebrospinal fluid in term and preterm neonates withoutbacterial meningitis
Age
MeanWBC/mm
(range or 90thpercentile)
ANC/mm orpercent PMNs (range)
Mean protein(mg/dL)
(range or ±SD)
Mean glucose(mg/dL)
(range or ±SD)
Term neonates evaluated in the nursery setting
0 to 24 hours (n = 135)*
5 (0 to 90) 3/mm (0 to 70) 63 (32 to 240) 51 (32 to 78)
0 to 10 days (n = 87)
8.2 (0 to 32) 61.3 percent 90 (20 to 170) 52 (34 to 119)
0 to 32 days (n = 24)
11 (1 to 38) 21 percent (0 to100)
NR NR
Term neonates evaluated in the emergency department setting
0 to 7 days (n = 17)
15.3 (1 to 130) 4.4/mm (0 to 65) 80.8 (±30.8) 45.9 (±7.5)
0 to 7 days (n = 118)
8.6 (90 percentile:26)
NR 106.4 (90percentile: 153)
NR
1 to 28 days (n = 297)
6.1 (0 to 18) NR 75.4 (15.8 to 131) 45.3 (30 to 61)
0 to 30 days (n = 108)
7.3 (0 to 130) 0.8/mm (0 to 65) 64.2 (±24.2) 51.2 (±12.9)
8 to 14 days (n = 101)
3.9 (90 percentile:9)
NR 77.6 (90percentile: 103)
NR
8 to 14 days (n = 33)
5.4 (0 to 18) 0.1/mm (0 to 1) 69 (±22.6) 54.3 (±17)
15 to 22 days (n = 107)
4.9 (90 percentile:9)
NR 71 (90 percentile:106)
NR
15 to 21 days (n = 25)
7.7 (0 to 62) 0.2/mm (0 to 2) 59.8 (±23.4) 46.8 (±8.8)
22 to 28 days (n = 141)
4.5 (90 percentile:9)
NR 68.7 (90percentile: 85)
NR
22 to 30 days (n = 33)
4.8 (0 to 18) 0.1/mm (0 to 1) 54.1 (±16.2) 54.1 (±16.2)
Preterm or low birth weight neonates
0 to 28 days (n = 30 )
9 (0 to 29) 57.2 percent 115 (65 to 150) 50 (24 to 63)
0 to 32 days (n = 22 )
7 (0 to 28) 16 percent (0 to100)
NR NR
Very low birth weight neonates
<1000 g
0 to 7 days (n = 6)
3 (1 to 8) 11 percent (0 to 50) 162 (115 to 222) 70 (41 to 89)
8 to 28 days (n = 17)
4 (0 to 14) 8 percent (0 to 66) 159 (95 to 370) 68 (33 to 217)
29 to 84 days (n = 15)
4 (0 to 11) 2 percent (0 to 36) 137 (76 to 269) 49 (29 to 90)
1000 to 1500 g
0 to 7 days (n = 8)
4 (1 to 10) 4 percent (0 to 28) 136 (85 to 176) 74 (50 to 96)
33
[1]3
¶[2]
¶[3]
Δ
[4]3
[5]th th
[6]
[4]◊ 3
[5]th th
[4]3
[5]th th
[4]3
[5]th th
[4]3
§ ¶[2]
¥ ¶[3]
[7]
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 13/19
8 to 28 days
(n = 14)
7 (0 to 44) 10 percent (0 to 60) 137 (54 to 227) 59 (39 to 109)
29 to 84 days
(n = 11)
8 (0 to 23) 11 percent (0 to 48) 122 (45 to 187) 47 (31 to 76)
WBC: white blood cell count; ANC: absolute neutrophil count; PMNs: polymorphonuclear leukocytes; SD: standard
deviation; NR: not reported; CSF: cerebrospinal fluid.
* CSF obtained from term neonates without any obvious pathology.
¶ CSF obtained from hospitalized neonates at high risk for infection (eg, unexplained jaundice, prolonged rupture of
membranes, maternal fever, etc); infection excluded by sterile cultures (CSF, blood, urine) and lack of clinical evidence of
bacterial or viral infection.
Δ CSF obtained in the emergency department during evaluation for possible infection; infection was excluded by sterile
cultures (CSF, blood, urine, and negative polymerase chain reaction for enterovirus).
◊ Only two infants had CSF WBC >30/mm : one <7 days of age with 130 WBC/mm , and one 15 to 21 days of age with
62 WBC/mm .
§ Includes 29 preterm infants and 1 infant who was 2190 g at 40 weeks' gestation.
¥ Includes all infants with birth weight <2500 g.
References: 1. Naidoo BT. The cerebrospinal fluid in the healthy newborn infant. S Afr Med J 1968; 42:933.2. Sarff LD, Lynn H, Platt MD, et al. Cerebrospinal fluid evaluation in neonates: Comparison of high risk infants withand without meningitis. J Pediatr 1976; 88:473.
3. Pappu L. CSF cytology in the neonate. Am J Dis Child 1982; 136:297.4. Ahmed A. Cerebrospinal fluid values in the term neonate. Pediatr Infect Dis J 1996; 15:298.5. Chadwick SL, Wilson JW, Levin JE, Martin JM. Cerebrospinal fluid characteristics of infants who present to theemergency department with fever: establishing normal values by week of age. Pediatr Infect Dis J 2011; 30:e63.
6. Byington CL, Kendrick J, Sheng X. Normative cerebrospinal fluid profiles in febrile infants. J Pediatr 2011; 158:130.7. Rodriguez AF, Kaplan SL, Mason EO. Cerebrospinal fluid values in the very low birth weight infant. J Pediatr 1990;116:971.
Graphic 54464 Version 14.0
3 3
3
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 14/19
Suggested antimicrobial regimens in the management of neonatal sepsis in termand late preterm infants
Antibiotic regimen
Empiric therapy
Early onset (<7 days) Ampicillin AND gentamicin
Late onset (≥7 days): Admitted from the community Ampicillin AND gentamicin
Late onset (≥7 days): Hospitalized since birth Gentamicin AND vancomycin
Special circumstances:
Suspected meningitis early onset Ampicillin AND gentamicin*
Suspected meningitis late onset, admitted fromthe community
Ampicillin, gentamicin, AND cefotaxime
Suspected meningitis late onset, hospitalizedsince birth
Gentamicin, vancomycin, AND cefotaxime
Suspected pneumonia Ampicillin AND gentamicin
Alternatives:Ampicillin AND cefotaxime, ORVancomycin AND cefotaxime, ORVancomycin AND gentamicin
Suspected infection of soft tissues, skin, joints, orbones (S. aureus is a likely pathogen)
Vancomycin or vancomycin AND nafcillin
Suspected intravascular catheterrelated infection Vancomycin AND gentamicin
Suspected infection due to organisms found in thegastrointestinal tract (eg, anaerobic bacteria)
Ampicillin, gentamicin, AND clindamycin
Alternatives:Ampicillin, gentamicin, AND metronidazole ORPiperacillintazobactam AND gentamicin
Pathogenspecific therapy
Group B Streptococcus Penicillin G
Escherichia coli: Ampicillinsensitive Ampicillin
Escherichia coli: Ampicillinresistant Cefotaxime
Alternative:Meropenem
Multidrugresistant gramnegative bacilli (includingESBLproducing organisms)
Meropenem
Listeria monocytogenes Ampicillin AND gentamicin
Methicillinsusceptible S. aureus (MSSA) Nafcillin OR cefazolin
Methicillinresistant S. aureus (MRSA) Vancomycin
Coagulasenegative staphylococci Vancomycin
ESBL: extendedspectrum betalactamase. * Cefotaxime should be added to the empiric regimen for suspected earlyonset meningitis if the CSF Gram stain revealsgramnegative bacilli.
References:
1. Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Principles and Practice of Pediatric Infectious
Diseases, 4th ed, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, Philadelphia 2012. p.538.
2. Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious diseases of the Fetus and Newborn Infant, 7th ed,
Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010. p.222.
3. American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee on
Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.
4. American Academy of Pediatrics. Escherichia coli and other Gramnegative bacilli (septicemia and meningitis in
neonates). In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed),
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 15/19
American Academy of Pediatrics, Elk Grove Village, IL 2015. p.340.
Graphic 102574 Version 3.0
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 16/19
Common bacterial agents causing neonatal sepsis in term infants
Bacterial speciesFrequency of isolation
Earlyonset Lateonset
Group B Streptococcus +++ +++
Escherichia coli +++ ++
Klebsiella spp. + +
Enterobacter spp. + +
Listeria monocytogenes + +
Other enteric gramnegatives + +
Nonenteric gramnegatives* + +
Viridans streptococci + +
Staphylococcus aureus + +++
Citrobacter spp. 0 +
Salmonella spp. 0 +
Coagulasenegative staphylococci 0 +
Enterococcus spp. 0 +
+++: commonly associated; ++: frequently associated; +: occasionally associated; 0: rarely associated.
* Includes nontypable Hemophilus influenzae and Neisseria meningitidis.
Adapted from: Edwards MS, Baker CJ. Bacterial infections in the neonate. In: Principles and Practice of Pediatric Infectious
Disease, 4th ed, Long SS, Pickering LK, Prober CG. Elsevier Saunders, Philadelphia 2012.
Graphic 61061 Version 6.0
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 17/19
Intravenous treatment of earlyonset group B streptococcal infections
Site(s) of infection Empirical therapyDefinitivetherapy*
Durationof
therapy
Bacteremia/sepsis/pneumonia Ampicillin 150 mg/kg every 12 hours Penicillin G: 50,000 to100,000 units/kg perday divided every 12hours
10 days
PLUS
Gentamicin 4 mg/kg every 24 hours forinfants born at ≥35 weeks gestation; 3mg/kg every 24 hours for infants born at<35 weeks gestation
Meningitis Ampicillin 100 to 150 mg/kg every 8 hours Penicillin G: 250,000to 450,000 units/kgper day divided every8 hours
14 to 21daysPLUS
Gentamicin 4 mg/kg every 24 hours forinfants born at ≥35 weeks gestation; 3mg/kg every 24 hours for infants born at<35 weeks gestation
GBS: Group B streptococcus; CSF: cerebrospinal fluid. * Definitive therapy should not be started until GBS is identified by culture; clinical improvement is evident; and formeningitis, CSF is sterile at 24 to 48 hours of therapy. ¶ 14 days is sufficient for uncomplicated cases of GBS meningitis.
References: 1. Medications. In: Guidelines for Acute Care of the Neonate, 22nd Ed, Adams JM, Fernandes CJ (Eds), Baylor Collegeof Medicine, Houston, TX 2014. p.89.
2. American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee onInfectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.
3. American Academy of Pediatrics. Tables of antibacterial drug dosages, Table 4.2. In: Red Book: 2015 Report of theCommittee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village,IL 2015. p.882.
4. Rao SC, Srinivasjois R, Hagen R, et al. One dose per day compared to multiple doses per day of gentamicin fortreatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011 Nov 9(11).
Graphic 71720 Version 8.0
¶
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 18/19
Intravenous treatment of lateonset group B streptococcal infections in neonatesand young infants
Site(s) of infection Empirical therapy* Definitive therapy Duration of therapy
Bacteremia without a focus Ampicillin, nafcillin, or
vancomycin
PLUS
Gentamicin or cefotaxime
Penicillin G
75,000 to 150,000 units/kg
per day divided every 8
hours
10 days
Meningitis Ampicillin and/or
vancomycin
PLUS
Gentamicin or cefotaxime
Penicillin G
450,000 to 500,000
units/kg per day divided
every 6 hours
14 to 21 days
Cellulitis/adenitis Nafcillin or vancomycin
PLUS
Gentamicin or cefotaxime
Penicillin G
75,000 to 150,000 units/kg
per day divided every 8
hours
10 to 14 days
Septic arthritis Nafcillin or vancomycin
PLUS
Cefotaxime
Penicillin G
75,000 to 150,000 units/kg
per day divided every 8
hours
14 to 21 days
Osteomyelitis Nafcillin or vancomycin
PLUS
Cefotaxime
Penicillin G
75,000 to 150,000 units/kg
per day divided every 8
hours
21 to 28 days
Urinary tract infection Ampicillin, nafcillin, or
vancomycin
PLUS
Gentamicin or cefotaxime
Penicillin G
75,000 to 150,000 units/kg
per day divided every 8
hours
10 days
The antibiotic doses listed above are for use in neonates and young infants age >1 week and body weight ≥1 kgwith normal renal function. For additional dosing detail, refer to the Lexicomp pediatric and neonatal druginformation monographs included within UpToDate.
GBS: group B streptococcus; CSF: cerebrospinal fluid.
* Selection will depend on age and presumed source of infection (maternal, hospital, or community).
¶ Definitive therapy should be started once GBS is identified by culture; clinical improvement is evident; and for
meningitis, CSF is sterile at 24 to 48 hours of therapy.
References: 1. American Academy of Pediatrics. Group B streptococcal infections. In: Red Book: 2015 Report of the Committee onInfectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, 2015. p.745.
2. American Academy of Pediatrics. Tables of antibacterial drug dosages, Table 4.2. In: Red Book: 2015 Report of theCommittee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village,IL 2015. p.882.
Graphic 66906 Version 8.0
¶
5/17/2017 Management and outcome of sepsis in term and late preterm infants - UpToDate
https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants/print?source=related_link 19/19
Contributor DisclosuresMorven S Edwards, MD Grant/Research/Clinical Trial Support: Pfizer Inc. [Group B
Streptococcus]. Leonard E Weisman, MD Grant/Research/Clinical Trial Support: Vax-Immune [Ureaplasmadiagnosis, vaccines, antibodies, other medical diagnostics and pre-analytical devices]. Consultant/AdvisoryBoards: Glaxo-Smith Kline [Malaria vaccine]; NIAID [Staphylococcus aureus (Mupirocin)]. Patent Holder:Baylor College of Medicine [Ureaplasma diagnosis, vaccines, antibodies, process for preparing biologicalsamples]. Equity Ownership/Stock Options: Vax-Immune [Ureaplasma diagnosis, vaccines, antibodies, othermedical diagnostics and pre-analytical devices]. Equity Ownership/Stock Options (Spouse): Vax-Immune[Ureaplasma diagnosis, vaccines, antibodies, other medical diagnostics and pre-analyticaldevices]. Sheldon L Kaplan, MD Grant/Research/Clinical Trial Support: Pfizer [S. pneumoniae (PCV13,Linezolid)]; Cubist [S. aureus (Tedizolid)]; Forest Lab [Osteomyelitis (Ceftaroline)]. Consultant/AdvisoryBoards: Pfizer [S. pneumoniae (PCV13, Linezolid); S. aureus (vaccine development)]; Theravance [S. aureus(Telavancin)]. Carrie Armsby, MD, MPH Nothing to disclose
Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these areaddressed by vetting through a multi-level review process, and through requirements for references to beprovided to support the content. Appropriately referenced content is required of all authors and mustconform to UpToDate standards of evidence.
Conflict of interest policy